Background: Fracture healing in osteoporotic patients is often delayed, leading to prolonged disability. Teriparatide, a recombinant form of parathyroid hormone (PTH 1–34), stimulates osteoblasts and enhances bone formation.
Methods: A prospective observational study was conducted in the Department of Orthopaedics, VMKV Medical College, Salem, involving 30 patients aged above 50 years with osteoporotic or delayed union fractures. All participants received standard surgical fixation followed by daily subcutaneous teriparatide 20 mcg for 24 weeks. Radiological Union Score (RUS) and Visual Analogue Scale (VAS) were assessed at baseline, 4, 8, 12, and 24 weeks.
Results: The mean age was 63.2 ± 7.6 years, with a female predominance. RUS scores improved significantly from 8.2 ± 1.4 to 17.8 ± 1.6 (p < 0.001) at 24 weeks, while mean VAS scores decreased from 8.5 ± 0.7 to 1.2 ± 0.5 (p < 0.001). No major adverse effects were reported.
Conclusion: Teriparatide significantly enhanced fracture healing and pain outcomes among osteoporotic patients, offering an effective adjunct in managing difficult fracture unions.
Keywords: Teriparatide, Fracture healing, Osteoporosis, Radiological Union Score, Visual Analogue Scale.
How to cite this article: Reddy GM, Karuppanan S, Baskar AA, Kumar S, Role Of Teriparatide In The Management Of Fracture Healing. Int J Drug Deliv Technol. 2026;16(4s): 147-156; DOI: 10.25258/ijddt.16.147-156